...
  • Apple, Inc AAPL
  • S&P 500 ETF Trust SPDR SPY
  • Alphabet Inc. - Class A Shares GOOGL
  • Microsoft Corporation MSFT
  • Meta Platforms Inc META
  • Netflix, Inc. NFLX
  • Amazon.com Inc. AMZN
  • Spotify Technology SA SPOT
    pali-img

    Palisade Bio Inc, Common Stock

    PALI

    NAQ

    $4.62

    -$0.19

    (-3.95%)

    1D
    Industry: Biotechnology Sector: Health Care

    Analyst Forecast

    Overview Returns Financials Ratios News FAQs

    Price Chart

    Key Metrics

    Market Cap info-icon
    This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
     $4.33M
    P/E Ratio info-icon
    This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
     NM
    Volume info-icon
    This is the total number of shares traded during the most recent trading day.
     26.33K
    Avg Volume info-icon
    This is the average number of shares traded during the most recent 30 days.
     25.74K
    Dividend Yield info-icon
    This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
     0.00%
    Beta info-icon
    This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
     1.29
    52-week Range info-icon
    This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
    $3.82 L
    $36.6 H
    $4.62

    About Palisade Bio Inc, Common Stock

    Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. more

    Industry: BiotechnologySector: Health Care

    Returns

    Time FramePALISectorS&P500
    1-Week Return-1.28%0.93%-0.23%
    1-Month Return-5.91%1.85%3.09%
    3-Month Return-15.1%1.27%4.99%
    6-Month Return-48.41%9.09%15.17%
    1-Year Return-81.45%13.44%28%
    3-Year Return-99.86%22.7%34.03%
    5-Year Return-99.98%71.25%101.06%
    10-Year Return-100%184.66%236.13%

    Financials

    Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
    Total Revenue15.39K13.52K-250.00K250.00K[{"date":"2019-12-31","value":6.16,"profit":true},{"date":"2020-12-31","value":5.41,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
    Cost of Revenue-146.00K168.00K167.00K4.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":86.9,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.4,"profit":true},{"date":"2023-12-31","value":2.38,"profit":true}]
    Gross Profit15.39K(132.48K)(168.00K)(167.00K)246.00K[{"date":"2019-12-31","value":6.26,"profit":true},{"date":"2020-12-31","value":-53.85,"profit":false},{"date":"2021-12-31","value":-68.29,"profit":false},{"date":"2022-12-31","value":-67.89,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
    Gross Margin100.00%(979.88%)(Infinity%)(66.80%)98.40%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-979.88,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":-66.8,"profit":false},{"date":"2023-12-31","value":98.4,"profit":true}]
    Operating Expenses8.50M9.30M41.85M15.31M13.09M[{"date":"2019-12-31","value":20.32,"profit":true},{"date":"2020-12-31","value":22.21,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":36.58,"profit":true},{"date":"2023-12-31","value":31.28,"profit":true}]
    Operating Income(8.63M)(9.30M)(41.85M)(15.72M)(12.85M)[{"date":"2019-12-31","value":-863169000,"profit":false},{"date":"2020-12-31","value":-929700000,"profit":false},{"date":"2021-12-31","value":-4185400000,"profit":false},{"date":"2022-12-31","value":-1572100000,"profit":false},{"date":"2023-12-31","value":-1284500000,"profit":false}]
    Total Non-Operating Income/Expense-(2.10M)12.15M1.45M530.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-17.29,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":11.91,"profit":true},{"date":"2023-12-31","value":4.36,"profit":true}]
    Pre-Tax Income(8.35M)(10.32M)(26.62M)(14.26M)(12.30M)[{"date":"2019-12-31","value":-835165100,"profit":false},{"date":"2020-12-31","value":-1032200000,"profit":false},{"date":"2021-12-31","value":-2661600000,"profit":false},{"date":"2022-12-31","value":-1426000000,"profit":false},{"date":"2023-12-31","value":-1230000000,"profit":false}]
    Income Taxes288.96K248.00K655.00K(1.46M)16.00K[{"date":"2019-12-31","value":44.12,"profit":true},{"date":"2020-12-31","value":37.86,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-223.05,"profit":false},{"date":"2023-12-31","value":2.44,"profit":true}]
    Income After Taxes-(10.57M)(27.27M)(12.80M)(12.32M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1057000000,"profit":false},{"date":"2021-12-31","value":-2727100000,"profit":false},{"date":"2022-12-31","value":-1279900000,"profit":false},{"date":"2023-12-31","value":-1231600000,"profit":false}]
    Income From Continuous Operations-(10.32M)(26.62M)(14.26M)(12.30M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1032200000,"profit":false},{"date":"2021-12-31","value":-2661600000,"profit":false},{"date":"2022-12-31","value":-1426000000,"profit":false},{"date":"2023-12-31","value":-1230000000,"profit":false}]
    Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
    Net Income(8.35M)(10.57M)(27.27M)(12.80M)(12.32M)[{"date":"2019-12-31","value":-835165100,"profit":false},{"date":"2020-12-31","value":-1057000000,"profit":false},{"date":"2021-12-31","value":-2727100000,"profit":false},{"date":"2022-12-31","value":-1279900000,"profit":false},{"date":"2023-12-31","value":-1231600000,"profit":false}]
    EPS (Diluted)(13.39)(13.42)17.08(16.53)(7.96)[{"date":"2019-12-31","value":-78.4,"profit":false},{"date":"2020-12-31","value":-78.57,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-96.78,"profit":false},{"date":"2023-12-31","value":-46.6,"profit":false}]

    Ratios

    Liquidity

    These ratios help you determine the liquidity of the company. Higher is better.

    PALI
    Cash Ratio 4.57
    Current Ratio 4.84

    Asset Efficiency

    These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

    PALI
    ROA (LTM) -62.64%
    ROE (LTM) -113.28%

    Liabilities

    These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

    PALI
    Debt Ratio Lower is generally better. Negative is bad. 0.20
    Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.80
    Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. 1.15

    Valuation

    These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

    PALI
    Trailing PE NM
    Forward PE NM
    P/S (TTM) 14.03
    P/B 0.31
    Price/FCF NM
    EV/R 234.89
    EV/Ebitda 0.70
    PEG NM

    News

    Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences | PALI Stock News

    Palisade Bio and Strand Life Sciences advance precision medicine for ulcerative colitis with promising PDE4 biomarkers, paving the way for personalized UC therapies.

    21 Jun, 2024 a 12:15 pm Stock Titan

    Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

    – Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics

    21 Jun, 2024 a 12:15 pm GlobeNewswire

    PALI Stock Earnings: Palisade Bio Beats EPS for Q1 2024

    Palisade Bio (NASDAQ: PALI ) just reported results for the first quarter of 2024. Palisade Bio reported earnings per share of -$4.59. This was above the analyst estimate for EPS of -$4.80. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future” The post PALI Stock Earnings: Palisade Bio Beats EPS for Q1 2024 appeared first on InvestorPlace .

    14 May, 2024 a 2:53 am InvestorPlace

    Palisade Bio Welcomes New Board Member, Eyes Strategic Growth

    Palisade Bio (PALI) has provided an announcement. In a significant corporate update, the Company has announced the addition of Margery Fischbein to…

    10 May, 2024 a 9:02 pm TipRanks

    Palisade Bio Appoints Margery Fischbein to its Board of Directors

    Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally

    7 May, 2024 a 12:30 pm GlobeNewswire

    Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules | PALI Stock News

    Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has closed its previously

    7 May, 2024 a 11:30 am Stock Titan

    Discover more

    Tsla

    Tesla, Inc.
    aaple

    Apple, Inc.
    GOOGL

    Alphabet Inc. - Class A Shares
    META

    Meta Platforms Inc
    AMZN

    Amazon.com Inc.
    Microsoft

    Microsoft Corporation
    NVDA

    NVIDIA Corporation
    BRK

    Berkshire Hathaway Inc. Hld B
    LLY

    Eli Lilly and Company

    FAQs

    What is Palisade Bio Inc share price today?

    Palisade Bio Inc (PALI) share price today is $4.62

    Can Indians buy Palisade Bio Inc shares?

    Yes, Indians can buy shares of Palisade Bio Inc (PALI) on Vested. To buy Palisade Bio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PALI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

    Can Fractional shares of Palisade Bio Inc be purchased?

    Yes, you can purchase fractional shares of Palisade Bio Inc (PALI) via the Vested app. You can start investing in Palisade Bio Inc (PALI) with a minimum investment of $1.

    How to invest in Palisade Bio Inc shares from India?

    You can invest in shares of Palisade Bio Inc (PALI) via Vested in three simple steps:

    • Click on Sign Up or Invest in PALI stock at the top of this page
    • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
    • Transfer USD funds to your US Brokerage account and start investing in Palisade Bio Inc shares
    What is Palisade Bio Inc 52-week high and low stock price?

    The 52-week high price of Palisade Bio Inc (PALI) is $36.6. The 52-week low price of Palisade Bio Inc (PALI) is $3.82.

    What is Palisade Bio Inc price-to-earnings (P/E) ratio?

    The price-to-earnings (P/E) ratio of Palisade Bio Inc (PALI) is NM

    What is Palisade Bio Inc price-to-book (P/B) ratio?

    The price-to-book (P/B) ratio of Palisade Bio Inc (PALI) is 0.31

    What is Palisade Bio Inc dividend yield?

    The dividend yield of Palisade Bio Inc (PALI) is 0.00%

    What is the Market Cap of Palisade Bio Inc?

    The market capitalization of Palisade Bio Inc (PALI) is $4.33M

    What is Palisade Bio Inc’s stock symbol?

    The stock symbol (or ticker) of Palisade Bio Inc is PALI

    Feedback

    Signup to access all features and start your US investing journey!

    • Open your account in minutes
    • Take your portfolio global, starting at just $1
    Get started

    Add ticker to compare

    white-logo

    222 N. Sepulveda Blvd, Suite 10-124, 
El Segundo, CA 90245, USA

    5 Vivekanand Villa, 139 S V Road, Andheri West, Mumbai, Mumbai City, Maharashtra, India, 400058

    help@vestedfinance.co | +919513375607

    Google_Play_Store
    Apple_store
    instagram twitter linkedin

    Company

    Explore Products

    MOST POPULAR ON VESTED

    Popular US Stocks 1

    Apple Microsoft Alphabet (Google) Amazon NVIDIA Meta Platforms (Facebook) Berkshire Hathaway Tesla Eli Lilly Visa UnitedHealth Walmart JPMorgan Chase Exxon Mobil Broadcom Johnson & Johnson Mastercard Procter & Gamble Oracle Home Depot Chevron Adobe Merck Costco AbbVie

    Popular US ETFs 2

    SPDR S&P 500 ETF Trust iShares Core S&P 500 ETF Vanguard S&P 500 ETF Vanguard Total Stock Market ETF Invesco QQQ Trust Series I Vanguard FTSE Developed Markets ETF Vanguard Value ETF Vanguard Total Bond Market ETF iShares Core MSCI EAFE ETF iShares Core U.S. Aggregate Bond ETF Vanguard Growth ETF iShares Russell 1000 Growth ETF Vanguard FTSE Emerging Markets ETF iShares Core MSCI Emerging Markets ETF iShares Core S&P Mid-Cap ETF Vanguard Dividend Appreciation ETF iShares Core S&P Small-Cap ETF SPDR Gold Shares Vanguard Total International Stock ETF Vanguard Total International Bond ETF Vanguard Mid-Cap ETF Vanguard Information Technology ETF iShares Russell 2000 ETF Technology Select Sector SPDR ETF iShares Russell 1000 Value ETF

    Curated Portfolios (Vests)

    Moat Bitcoin Vest SAAS Multi-Asset Class - Aggressive Multi-Asset Class - Moderate Multi-Asset Class - Conservative Digital Cash Deglobalization Vest BlackRock Smart Beta Aging Vest Swensen Portfolio All Weather

    Others

    Calculators Terms and conditions Privacy Policy Everything Legal
    • 1Top 25 as per Marketwatch
    • 2Top 10 US Stocks from S&P 500 index as per market capitalization
    • 1Total number of KYCed accounts on Vested as of November 2023
    • 2The above portfolio is not meant to represent any real person's portfolio or a suggested portfolio but to show what a typically diversified portfolio might look like
    • 3US Stocks and ETFs are powered by VF Securities, Inc (Member FINRA/SIPC)

    Risk Disclosure - US Markets

    Global

    Vested Finance Inc. is an investment adviser in California. Vested Finance Inc. is registered with the Securities and Exchange Commission (SEC). Registration of an investment adviser dVested Finance Inc. is an investment adviser in California. Vested Finance Inc. is registered with the Securities and Exchange Commission (SEC). Registration of an investment adviser does not imply any specific level of skill or training and does not constitute an endorsement of the firm by the Commission. Vested Finance Inc. only transacts business in states in which it is properly registered or is excluded or exempted from registration. A copy of Vested Finance Inc.’s current written disclosure brochure filed with the SEC which discusses among other things, Vested Finance Inc.’s business practices, services and fees, is available through the SEC’s website at: www.adviserinfo.sec.gov. You can also find a copy of our customer relationship summary (Form CRS) here.

    All securities are offered through VF Securities, Inc. (member FINRA/SIPC). More information about this firm can be found at www.brokercheck.finra.org and at SIPC.org. This website is maintained and published by Vested Finance Inc. Vested Finance Inc., VF Securities Inc., and Vested Private Services Limited are wholly owned subsidiaries of Vested Holding Corp., referred to herein as Vested Group. You can learn more about VF Securities, Inc. on FINRA’s Broker.… Read more

    All investing carries risk. Past performance is not indicative of future returns, which may vary. Investments in stocks and Exchange Traded Funds (“ETFs”) may decline in value. Online trading has inherent risk due to system response and access times that may be affected by various factors, including but not limited to market conditions and system performance. An investor should understand such facts before trading. The risks associated with investing in international securities [including US-listed American Depositary Receipts (“ADRs”) and ETFs that contain non-US securities include, among others, country/political risk relating to the government in the home country; exchange rate risk if the country’s currency is devalued; and inflationary/purchasing power risks if the currency of the home country becomes less valuable as the general level of prices for goods and services rises.

    The information and services provided on this website are not provided to and may not be used by any person or entity in any jurisdiction where the provision or use thereof would be contrary to applicable laws, rules or regulations of any governmental authority or regulatory or self-regulatory organization or where Vested Group is not authorized to provide such information or services.

    All information published on this website is for informational purposes only and no part of it must be construed as an offer to sell or buy a security.

    No information published on the website is intended to be investment advice, portfolio management or as any form of research analysis, directly or indirectly. Each DIY Vest is created by individual users of this website, and Vested Group does not have any role in the selection of stocks for DIY Vests. The users of the website shall be solely responsible for any action taken by them pursuant to the information contained herein, including any investment decision with respect to transaction in securities for which a platform is made available on this website.

    Vested Group makes no warranty or representation, either express or implied, on any product or service offered through its website/platform. Vested Group shall not be liable in any manner whatsoever for any damage or loss, whatsoever caused, in connection with the services provided on this website/platform. Hyperlinks or external websites which may be accessed through this website, if any, are for the user’s convenience and Vested Group does not take any responsibility for the same. Any description of, reference to, or links to other products, publications or services does not constitute an endorsement, authorization, solicitation, advertisement, sponsorship by or affiliation with Vested Group with respect to any linked site or its sponsor, unless expressly stated by Vested Group. While reasonable care has been exercised to ensure that the information published on this website is adequate and reliable, no representation is made by Vested Group as to its accuracy, completeness, or fitness for any purpose and Vested Group, its affiliates, subsidiaries, and employees accept no liability of whatsoever nature for any direct or consequential loss, including without limitation any loss of profits, arising from reliance on this information.

    Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investors’ sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor.

    Read less

    Risk Disclosure - Indian Markets

    india

    P2P lending and INR Bonds are offered through Vested Services Private Limited. Such investments are subject to risks including loss of principal.

    If you have any questions about this disclaimer or in relation to information and services provided through this website, please contact us at help@vestedfinance.co / +919513375607 while providing your contact details for us to correspond further, if required. We welcome your questions and suggestions about us.

     

    By using our website, you agree to our terms and privacy policy.

    Scroll to Top